Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants

Andrew A. Nierenberg, George I. Papakostas, Timothy Petersen, Heidi D. Montoya, John J. Worthington, Joyce Tedlow, Jonathan E. Alpert, Maurizio Fava

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Lithium augmentation, the most studied augmentation strategy for depression, has not been evaluated in patients with a history of non-response to multiple antidepressants. The objective of this study was to assess the efficacy of lithium augmentation for patients with a history of treatment resistant depression who also failed a prospective trial of nortriptyline. We enrolled 92 subjects with treatment resistant depression. Treatment resistance was defined by at least one, but no more than five, adequate trials of antidepressants during the current episode. Subjects were treated with nortriptyline (NT) for 6 weeks. Those subjects who tolerated NT for 6 weeks and whose depression did not respond (n=35) were randomized to receive either lithium (n = 18) or placebo (N = 17) augmentation of nortriptyline for an additional 6 weeks. Response was defined as an equal to or greater than 50% decrease in HAM-D-17 scores. After 6 weeks of double-blind augmentation, 12.5% of subjects responded to lithium and 20.0% to placebo. Our results revealed no significant difference between lithium and placebo augmentation. While lithium augmentation seems to be useful in depression refractory to a single medication in some studies, our data suggest limited usefulness of this option for patients refractory to multiple treatments. More definitive data await the outcome of the NIMH Sequential Treatment Alternatives to Relieve Depression (STAR*D) study.

Original languageEnglish (US)
Pages (from-to)92-95
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume23
Issue number1
DOIs
StatePublished - Feb 2003
Externally publishedYes

Fingerprint

Nortriptyline
Lithium
Antidepressive Agents
Treatment-Resistant Depressive Disorder
Placebos
Depression
National Institute of Mental Health (U.S.)
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Nierenberg, A. A., Papakostas, G. I., Petersen, T., Montoya, H. D., Worthington, J. J., Tedlow, J., ... Fava, M. (2003). Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. Journal of Clinical Psychopharmacology, 23(1), 92-95. https://doi.org/10.1097/00004714-200302000-00013

Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. / Nierenberg, Andrew A.; Papakostas, George I.; Petersen, Timothy; Montoya, Heidi D.; Worthington, John J.; Tedlow, Joyce; Alpert, Jonathan E.; Fava, Maurizio.

In: Journal of Clinical Psychopharmacology, Vol. 23, No. 1, 02.2003, p. 92-95.

Research output: Contribution to journalArticle

Nierenberg, AA, Papakostas, GI, Petersen, T, Montoya, HD, Worthington, JJ, Tedlow, J, Alpert, JE & Fava, M 2003, 'Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants', Journal of Clinical Psychopharmacology, vol. 23, no. 1, pp. 92-95. https://doi.org/10.1097/00004714-200302000-00013
Nierenberg, Andrew A. ; Papakostas, George I. ; Petersen, Timothy ; Montoya, Heidi D. ; Worthington, John J. ; Tedlow, Joyce ; Alpert, Jonathan E. ; Fava, Maurizio. / Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. In: Journal of Clinical Psychopharmacology. 2003 ; Vol. 23, No. 1. pp. 92-95.
@article{486c9072ce9c493895f4583464cb3de0,
title = "Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants",
abstract = "Lithium augmentation, the most studied augmentation strategy for depression, has not been evaluated in patients with a history of non-response to multiple antidepressants. The objective of this study was to assess the efficacy of lithium augmentation for patients with a history of treatment resistant depression who also failed a prospective trial of nortriptyline. We enrolled 92 subjects with treatment resistant depression. Treatment resistance was defined by at least one, but no more than five, adequate trials of antidepressants during the current episode. Subjects were treated with nortriptyline (NT) for 6 weeks. Those subjects who tolerated NT for 6 weeks and whose depression did not respond (n=35) were randomized to receive either lithium (n = 18) or placebo (N = 17) augmentation of nortriptyline for an additional 6 weeks. Response was defined as an equal to or greater than 50{\%} decrease in HAM-D-17 scores. After 6 weeks of double-blind augmentation, 12.5{\%} of subjects responded to lithium and 20.0{\%} to placebo. Our results revealed no significant difference between lithium and placebo augmentation. While lithium augmentation seems to be useful in depression refractory to a single medication in some studies, our data suggest limited usefulness of this option for patients refractory to multiple treatments. More definitive data await the outcome of the NIMH Sequential Treatment Alternatives to Relieve Depression (STAR*D) study.",
author = "Nierenberg, {Andrew A.} and Papakostas, {George I.} and Timothy Petersen and Montoya, {Heidi D.} and Worthington, {John J.} and Joyce Tedlow and Alpert, {Jonathan E.} and Maurizio Fava",
year = "2003",
month = "2",
doi = "10.1097/00004714-200302000-00013",
language = "English (US)",
volume = "23",
pages = "92--95",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants

AU - Nierenberg, Andrew A.

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Montoya, Heidi D.

AU - Worthington, John J.

AU - Tedlow, Joyce

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

PY - 2003/2

Y1 - 2003/2

N2 - Lithium augmentation, the most studied augmentation strategy for depression, has not been evaluated in patients with a history of non-response to multiple antidepressants. The objective of this study was to assess the efficacy of lithium augmentation for patients with a history of treatment resistant depression who also failed a prospective trial of nortriptyline. We enrolled 92 subjects with treatment resistant depression. Treatment resistance was defined by at least one, but no more than five, adequate trials of antidepressants during the current episode. Subjects were treated with nortriptyline (NT) for 6 weeks. Those subjects who tolerated NT for 6 weeks and whose depression did not respond (n=35) were randomized to receive either lithium (n = 18) or placebo (N = 17) augmentation of nortriptyline for an additional 6 weeks. Response was defined as an equal to or greater than 50% decrease in HAM-D-17 scores. After 6 weeks of double-blind augmentation, 12.5% of subjects responded to lithium and 20.0% to placebo. Our results revealed no significant difference between lithium and placebo augmentation. While lithium augmentation seems to be useful in depression refractory to a single medication in some studies, our data suggest limited usefulness of this option for patients refractory to multiple treatments. More definitive data await the outcome of the NIMH Sequential Treatment Alternatives to Relieve Depression (STAR*D) study.

AB - Lithium augmentation, the most studied augmentation strategy for depression, has not been evaluated in patients with a history of non-response to multiple antidepressants. The objective of this study was to assess the efficacy of lithium augmentation for patients with a history of treatment resistant depression who also failed a prospective trial of nortriptyline. We enrolled 92 subjects with treatment resistant depression. Treatment resistance was defined by at least one, but no more than five, adequate trials of antidepressants during the current episode. Subjects were treated with nortriptyline (NT) for 6 weeks. Those subjects who tolerated NT for 6 weeks and whose depression did not respond (n=35) were randomized to receive either lithium (n = 18) or placebo (N = 17) augmentation of nortriptyline for an additional 6 weeks. Response was defined as an equal to or greater than 50% decrease in HAM-D-17 scores. After 6 weeks of double-blind augmentation, 12.5% of subjects responded to lithium and 20.0% to placebo. Our results revealed no significant difference between lithium and placebo augmentation. While lithium augmentation seems to be useful in depression refractory to a single medication in some studies, our data suggest limited usefulness of this option for patients refractory to multiple treatments. More definitive data await the outcome of the NIMH Sequential Treatment Alternatives to Relieve Depression (STAR*D) study.

UR - http://www.scopus.com/inward/record.url?scp=0037311094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037311094&partnerID=8YFLogxK

U2 - 10.1097/00004714-200302000-00013

DO - 10.1097/00004714-200302000-00013

M3 - Article

VL - 23

SP - 92

EP - 95

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -